Logo

TNO, Mitsubishi Pharma Enter siRNA Target Validation Pact

Sep 06, 2005

NEW YORK, Sept. 6 (GenomeWeb News) - Dutch biotech TNO and Mitsubishi Pharma of Japan have entered into a technology development collaboration for siRNA-based target validation studies.

 

Under the terms of the agreement, TNO will use its siRNA knockdown technology and disease models to further characterize a set of Mitsubishi's proprietary disease targets.

 

Financial terms of the agreement were not disclosed.

Breaking News
The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.